Stockscreener 앱 받기
15.09
11.81%
-2.02
시간 외 거래:
14.92
-0.17
-1.13%
전일 마감가:
$17.11
열려 있는:
$17
하루 거래량:
299.11K
Relative Volume:
3.10
시가총액:
$590.74M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-29.06%
1개월 성능:
-29.29%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$13.73
$18.23
1주일 범위
$13.73
$22.48
52주 변동 폭
$13.73
$26.25
Zenas Biopharma Inc Stock (ZBIO) Company Profile
명칭
Zenas Biopharma Inc
전화
857-271-2954
주소
1000 WINTER ST, SUITE 1200, WALTHAM
ZBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ZBIO | 15.09 | 590.74M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Zenas Biopharma Inc 주식(ZBIO)의 최신 뉴스
FMR LLC Acquires New Stake in Zenas BioPharma Inc - GuruFocus.com
Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Zenas BioPharma Raises $259M in IPO, Advances Phase 3 Trial Amid Growing R&D Investment | ZBIO Stock News - StockTitan
Zenas BioPharma Completes Targeted Enrollment of the Phase - GlobeNewswire
Zenas BioPharma Hits Milestone: Completes Enrollment in Largest-Ever IgG4-RD Trial | ZBIO Stock News - StockTitan
Zenas BioPharma Inc. (ZBIO) Quarterly 10-Q Report - Quartzy
Zenas BioPharma To Attend Upcoming Healthcare Investor Conferences - BERNAMA
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences - BERNAMA
TSX Global Base Metals EW Index (TXBE) QuotePress Release - The Globe and Mail
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
Arm Holdings Plc ADR (ARM-Q) QuotePress Release - The Globe and Mail
TSX Industrials EW Index (TXIE) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Zenas Bio: Recent IPO With Late-Stage Candidate (NASDAQ:ZBIO) - Seeking Alpha
Zenas started at buy by four banks on lead drug potential (NASDAQ:ZBIO) - Seeking Alpha
Zenas stock backed by Guggenheim on strong outlook for lead drug obexelimab - Investing.com Canada
Morgan Stanley bullish on Zenas Biopharma stock as obexelimab trials gain momentum - Investing.com Canada
Citi sees upside in Zenas Biopharma stock as obexelimab progresses in key trials - Investing.com Canada
Jefferies bullish on Zenas stock as obexelimab advances in autoimmune trials - Investing.com Canada
Biopharma financings surge to $86.2B in 2024, with $8.7B in September - BioWorld Online
Halda appoints new chief executive - The Pharma Letter
IgG4-related Disease Market to Show Remarkable Growth Trends - openPR
Last Week's 3 Biotech IPOs Prompt Huge Insider Buying - 24/7 Wall St.
Biotech IPO Shares Climb in Debuts After Deals Upsized - MSN
Zenas BioPharma CEO acquires $360k worth of company shares - Investing.com India
Zenas BioPharma CEO acquires $360k worth of company shares By Investing.com - Investing.com South Africa
Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering - The Korea Bizwire
Zenas BioPharma’s $225 Million IPO - Global Legal Chronicle
Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase ... - The Bakersfield Californian
Zenas BioPharma Announces Closing of Full Exercise of - GlobeNewswire
Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in - EIN News
Upstream Bio goes public amid spate of IPOs - The Pharma Letter
Waltham biotech joins IPO buzz, plans to list on Nasdaq - The Business Journals
Zenas BioPharma sees $15 million in stock purchases by Zebra Aggregator - Investing.com South Africa
Zenas BioPharma director acquires $999k in company stock By Investing.com - Investing.com South Africa
Zenas BioPharma director acquires $999k in company stock - Investing.com Canada
IPOs, GLP-1 vs. PD-1, and AI in biotech: a BioCentury podcast - BioCentury
Zenas BioPharma director buys $7.48m in company stock By Investing.com - Investing.com South Africa
Zenas BioPharma director buys $7.48m in company stock - Investing.com
Zenas BioPharma director Jason Raleigh acquires $15 million in company stock By Investing.com - Investing.com South Africa
Zenas BioPharma director Jason Raleigh acquires $15 million in company stock - Investing.com India
Fairmount Healthcare Fund II L.P. buys $5.1m of Zenas BioPharma stock - Investing.com India
SR One Capital management buys $38m of Zenas BioPharma stock - Investing.com Australia
Zenas Biopharma Inc (ZBIO) 재무 분석
Zenas Biopharma Inc (ZBIO)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):